GB0508715D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0508715D0
GB0508715D0 GBGB0508715.0A GB0508715A GB0508715D0 GB 0508715 D0 GB0508715 D0 GB 0508715D0 GB 0508715 A GB0508715 A GB 0508715A GB 0508715 D0 GB0508715 D0 GB 0508715D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
effect
substituents
man
text
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0508715.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0508715.0A priority Critical patent/GB0508715D0/en
Publication of GB0508715D0 publication Critical patent/GB0508715D0/en
Priority to ES06726942T priority patent/ES2329508T3/en
Priority to AT06726942T priority patent/ATE438642T1/en
Priority to JP2008508302A priority patent/JP2008539217A/en
Priority to CNA2006800232286A priority patent/CN101208331A/en
Priority to DE602006008292T priority patent/DE602006008292D1/en
Priority to EP06726942A priority patent/EP1877398B1/en
Priority to PCT/GB2006/001562 priority patent/WO2006117523A1/en
Priority to US11/912,792 priority patent/US20090221616A1/en
Priority to HK08104254.5A priority patent/HK1114385A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
GBGB0508715.0A 2005-04-29 2005-04-29 Chemical compounds Ceased GB0508715D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0508715.0A GB0508715D0 (en) 2005-04-29 2005-04-29 Chemical compounds
US11/912,792 US20090221616A1 (en) 2005-04-29 2006-04-27 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
CNA2006800232286A CN101208331A (en) 2005-04-29 2006-04-27 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
AT06726942T ATE438642T1 (en) 2005-04-29 2006-04-27 QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINKINASE INHIBITORS
JP2008508302A JP2008539217A (en) 2005-04-29 2006-04-27 Quinazoline derivatives as EGF and / or ERBB2 tyrosine kinase inhibitors
ES06726942T ES2329508T3 (en) 2005-04-29 2006-04-27 DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF EGF AND / OR TYROSINE QUINASE ERBB2.
DE602006008292T DE602006008292D1 (en) 2005-04-29 2006-04-27 CHINAZOLINE DERIVATIVES AS EGF AND / OR ERBB2 TYROSINE CHINASE INHIBITORS
EP06726942A EP1877398B1 (en) 2005-04-29 2006-04-27 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
PCT/GB2006/001562 WO2006117523A1 (en) 2005-04-29 2006-04-27 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
HK08104254.5A HK1114385A1 (en) 2005-04-29 2008-04-15 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0508715.0A GB0508715D0 (en) 2005-04-29 2005-04-29 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0508715D0 true GB0508715D0 (en) 2005-06-08

Family

ID=34674047

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0508715.0A Ceased GB0508715D0 (en) 2005-04-29 2005-04-29 Chemical compounds

Country Status (10)

Country Link
US (1) US20090221616A1 (en)
EP (1) EP1877398B1 (en)
JP (1) JP2008539217A (en)
CN (1) CN101208331A (en)
AT (1) ATE438642T1 (en)
DE (1) DE602006008292D1 (en)
ES (1) ES2329508T3 (en)
GB (1) GB0508715D0 (en)
HK (1) HK1114385A1 (en)
WO (1) WO2006117523A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2006064196A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Pyrazolopyrimidine compounds as antitumor agents
EP3549584A1 (en) 2013-03-12 2019-10-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer, and kras-mutant colon cancer
WO2015056782A1 (en) * 2013-10-17 2015-04-23 塩野義製薬株式会社 Novel alkylene derivative
EP3516071B1 (en) 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
WO2019197605A2 (en) 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
EP3986898B1 (en) * 2019-06-21 2023-03-15 F. Hoffmann-La Roche AG Egfr inhibitors for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997027841A1 (en) * 1996-01-31 1997-08-07 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
JP3270834B2 (en) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
ID29800A (en) * 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma 4-AMINO-KINAZOLIN AND KINOLIN DISTRICTS THAT HAVE INHIBITOR EFFECTS ON SIGNAL TRANSDUKSI MEDIUMED BY THYROSIN KINASE
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (en) * 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
RU2004116911A (en) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Quinazoline derivatives as anti-tumor agents
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
BRPI0413066A (en) * 2003-07-29 2006-10-17 Astrazeneca Ab quinazoline derivative, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof, of formula I, use and process for the preparation thereof, compound, pharmaceutical composition, and methods for producing an antiproliferative effect in an animal of warm blood, for the prevention or treatment of a tumor, to provide a selective egfr tyrosine kinase inhibitory effect, and to treat cancer in a warm-blooded animal
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2539022A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0414488A (en) * 2003-09-16 2006-11-14 Astrazeneca Ab quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods to produce an anti-proliferative effect in a warm-blooded animal, to prevent or treat tumors in a warm-blooded aminal, to provide a tyrosine kinase inhibitory effect of selective egfr in a warm-blooded animal and to treat cancer in a warm-blooded animal and process for the preparation of a quinazoline derivative
UA84167C2 (en) * 2003-09-16 2008-09-25 Астразенека Аб Quinazoline derivatives as tyrosine kinase inhibitors, process for the preparation thereof (variants), pharmaceutical composition based thereon
CN1882570B (en) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 Quinazoline derivatives
JP2007506716A (en) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (en) * 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
US20070232607A1 (en) * 2004-06-04 2007-10-04 Bradbury Robert H Quinazoline Derivatives as Erbb Receptor Tyrosine kinases

Also Published As

Publication number Publication date
HK1114385A1 (en) 2008-10-31
EP1877398B1 (en) 2009-08-05
US20090221616A1 (en) 2009-09-03
EP1877398A1 (en) 2008-01-16
DE602006008292D1 (en) 2009-09-17
JP2008539217A (en) 2008-11-13
WO2006117523A1 (en) 2006-11-09
ES2329508T3 (en) 2009-11-26
ATE438642T1 (en) 2009-08-15
CN101208331A (en) 2008-06-25

Similar Documents

Publication Publication Date Title
GB0309009D0 (en) Quinazoline derivatives
GB0508717D0 (en) Chemical compounds
NO20061320L (en) Chinazoline derivatives as antitumor agents
NO20062353L (en) quinazoline
WO2007008704A3 (en) Melanocortin receptor ligands
MX2009010595A (en) Pyrrolopyrimidine derivatives as jak3 inhibitors.
MX2009009774A (en) Quinoline derivatives as fungicides.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
UA93883C2 (en) Pyrazine derivatives useful as adenosine receptor antagonists
GB0508715D0 (en) Chemical compounds
MX2009011199A (en) Pyrimidine derivatives.
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MX2009007302A (en) Purine derivatives.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
GB0508314D0 (en) Organic compounds
MX2010002899A (en) Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
HK1112462A1 (en) Pyrazolopyrimidine compounds as antitumor agents
MX2011007165A (en) Pyridazinone derivatives.
DE602005005024D1 (en) SUBSTITUTED THIENO- AND THIAZOLOÄ2,3-DÜPYRIMIDINE AND Ä2,3-CÜPYRIDINE AS INHIBITORS OF TIE2
TW200745090A (en) Chemical compounds
MX2009005249A (en) Organic compounds.
ATE404554T1 (en) PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS
NZ595579A (en) 5-Difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole / (5-(difluoromethoxy)-3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)methanol
HK1122795A1 (en) Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)